Botanix Pharmaceuticals

Home
Australia
North Perth, WA
Botanix Pharmaceuticals

Botanix is a dermatology company developing novel treatments for common skin diseases and infections

Botanix Pharmaceuticals is a dermatology company developing novel treatments for common skin diseases and infections.

21/10/2025

Botanix Presents at Canaccord Conference

Chief Executive Officer Dr Howie McKibbon will present to institutional investors at today’s Canaccord Drug and Device Healthcare Conference in Noosa. For the balance of the week, Canaccord Genuity will host a Botanix investor roadshow.

View ASX Release: https://bit.ly/4o1X4lq

$BOT

19/10/2025

🔸 Botanix Releases Quarterly Reports 🔸

The Quarterly Activity Report and 4C Quarterly Cash Flow Report for Q1 FY2026 have been released. Quarter over quarter, total prescriptions for Sofdra® (sofpironium) increased 50% to 20,418 as operating cash outflow decreased 54% to $13.1 million. Net revenue was $7.1 million.

🔗 View Reports: http://bit.ly/3WNLDS8

$BOT

16/10/2025

📆 Quarterly Update Webinar | Registration Open

Join our executive team for the Company’s Quarterly Activity Report and 4C Quarterly Cash Flow Report Webinar on Monday 20 October at 11.00 am AEDT / 8.00 am AWST for an important update.

Pre-register 👉 https://us06web.zoom.us/webinar/register/WN_-oGtp6viSHG5NwrKmitAsw

$BOT

04/09/2025

🔸 ECCLOCK® approved in South Korea 🔸

Botanix announced that Dongwha Pharm. Co., Ltd. has received regulatory approval for ECCLOCK® gel, 5% (Sofpironium Bromide) in South Korea. Dongwha is a sublicensee of Botanix’s Japanese partner, Kaken Pharmaceutical Co. Ltd.

31/08/2025

🔸 Botanix Releases Annual Report 🔸

The Annual Report for FY2025 has been released. At year end, Botanix held $64.9 million cash and $15.3 million in undrawn debt. Operating costs are stable with no inventory purchases anticipated in 1H FY2026, and revenue is expected to increase quarterly. The Company is well funded to achieve profitability.

View Report 👉 https://bit.ly/BOT_Annual_Report

$BOT

25/08/2025

🔸 Dr Walker Joins Botanix Board 🔸

Botanix welcomes Patricia Walker, MD, PhD, to the Board. She brings extensive experience and learnings from previous board affiliations with leading dermatology companies and the insights of a working dermatologist. She has led drug development for numerous key dermatology products, including Sofdra™ (sofpironium), from a preclinical asset to Phase 3 before its acquisition by Botanix.

View ASX Release 👉 https://bit.ly/BOT-Patricia-Walker

$BOT

12/08/2025

🔸 Botanix presentation at Canaccord Genuity event 🔸

Chief Executive Officer Dr Howie McKibbon will present at the Canaccord Genuity Annual Growth Conference in Boston, MA, attracting institutional fund managers worldwide. Some of the most promising growth companies, including those in the healthcare and life sciences sectors, will present during the event.

View ASX Release 👉 https://bit.ly/BOT-Canaccord

$BOT

27/07/2025

🔸 Botanix Releases Quarterly Reports 🔸

Quarterly Reports for Q4 FY2025 have been released. During the quarter, Botanix raised A$40m in capital, established a loan facility of up to the euro equivalent of US$30 million, and had A$64.9m cash on 30 June. With operating costs stable and revenues expected to rise, Botanix is well funded to support Sofdra™ (sofpironium) to profitability.

View Reports 👉 https://bit.ly/BOT-Quarterly-30June2025

$BOT

24/07/2025

📆 28 July Quarterly Update Webinar – Registration Open

Join our executive team for the Company’s Quarterly Activity Report and 4c Cash Flow Webinar on Monday 28 July 9:00 am AEST / 7:00 am AWST for an important update.

When: Monday 28 July 9:00 am AEST | 7:00 am AWST
Pre-register: https://bit.ly/BOT-QuarterlyUpdate

$BOT

04/07/2025

📆 8 July Commercial Day Webinar – Registration Open

Join our executive team for the Company’s Sofdra™ Launch Update Webinar on Tuesday 8 July 9:30am AEST / 7:30am AWST to receive a comprehensive look at the strong initial demand and performance of Sofdra™.

When: Tuesday 8 July 9:30am AEST | 7:30am AWST
🔗Pre-register: https://bit.ly/BOT-Sofdra-Launch-Webinar

$BOT

30/06/2025

is pleased to share that an article featuring sofpironium topical gel, 12.45% (Sofdra) appears in the July 2025 issue of the peer-reviewed Journal of the American Academy of Dermatology. The article presents pooled efficacy and safety results from 2 phase 3 randomized, controlled, double-blind studies that formed the basis for US Food and Drug Administration approval of Sofdra.

Read the article: https://bit.ly/BOT_JAAD

$BOT

22/06/2025

is pleased to have been featured in Dr Boreham’s Crucible, a column focusing on the Australian biotechnology and healthcare sectors. The interview with CEO, Dr Howie McKibbon includes in-depth look at Botanix and its fulfilment platform, commercialization strategies, and an update on the launch of Sofdra™ (sofpironium) gel, 12.45% in the US.

Read the full report 👉 https://bit.ly/BOT-Biotech-Daily

$BOT

Address

Level 1, 50 Angove Street
North Perth, WA
6006

Telephone

+61865552945

Website

https://www.botanixpharma.com/

Alerts

Be the first to know and let us send you an email when Botanix Pharmaceuticals posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Contact The Practice

Send a message to Botanix Pharmaceuticals:

Shortcuts

Want your practice to be the top-listed Clinic in North Perth?

Botanix Pharmaceuticals (ASX:BOT)

Botanix Pharmaceuticals Limited (ASX:BOT) is a clinical stage medical dermatology company based in Perth, Australia and Philadelphia, PA. The Company’s focus is the development of safe and effective topical treatments for acne, psoriasis, atopic dermatitis and other skin conditions. The active ingredient contained in Botanix products is a synthetic form of a widely studied natural compound. Treatment targets include inflammation, deterioration of the of the skin barrier, skin cell proliferation, pruritus (itch), excess sebum production and bacterial infection.

Botanix has an exclusive license to use a proprietary drug delivery system (PermetrexTM) for direct skin delivery of active pharmaceuticals in all skin diseases. Botanix is working with multiple parties to test the application of PermetrexTM on both a fee-for-service and traditional license basis.

Botanix pursues a rapid clinical development strategy aimed at accelerating product commercialisation. The patient treatment duration of clinical studies is generally completed within a 4 to 12-week timeframe.

The Company completed its first acne patient studies with BTX 1503 in January 2018 and has commenced a Phase 2 clinical trial in June 2018 with completion expected in mid-2019. The Phase 1b BTX 1204 atopic dermatitis patient study concluded in June 2018 and preparation is underway for a Phase 2 clinical trial. The Phase 1b BTX 1308 psoriasis patient study is due to commence in 4Q 2018.